ArticleInternational journal of molecular sciences2018
The Cyanthin Diterpenoid and Sesterterpene Constituents of Hericium erinaceus Mycelium Ameliorate Alzheimer's Disease-Related Pathologies in APP/PS1 Transgenic Mice.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 82 citations in OpenAlex.
- Acute Effects of Naturally Occurring Guayusa Tea and Nordic Lion's Mane Extracts on Cognitive Performance.Nutrients · 2023Trial
- A multi-target approach using Moringa oleifera leaf extract in ameliorating PTZ-induced epilepsy-like neurobehavior in male rats: in vivo and in silico study.Metabolic brain disease · 2026Article
- Article
- Chemistry and bioactivities of erinacines from Hericium fungi.Journal of natural medicines · 2026Review
- Recent Advances in Erinacine A: Preparation, Biological Activities, and Biosynthetic Pathway.Molecules (Basel, Switzerland) · 2026Review
- Neuroprotective Terpenoids Derived fromInternational journal of molecular sciences · 2025Article
- Bioactive Polysaccharides fromMolecules (Basel, Switzerland) · 2025Review
- NRICM101 in combatting COVID-19 induced brain fog: Neuroprotective effects and neurovascular integrity preservation in hACE2 mice.Journal of traditional and complementary medicine · 2025Article
- Unveiling the role of erinacines in the neuroprotective effects ofFrontiers in pharmacology · 2025Review
- NeuproGemp, a polyphenol-rich botanical formula, ameliorates Alzheimer's-like pathology in APP/PS1 mice via inhibition of human glutaminyl cyclase.Frontiers in pharmacology · 2025Article
- Exploring the Synergistic Effects of Erinacines on Microglial Regulation and Alzheimer's Pathology Under Metabolic Stress.CNS neuroscience & therapeutics · 2024Article
- Neuroprotective Effects of Dehydroepiandrosterone and Hericium erinaceus in Scopolamine-induced Alzheimer's Diseases-like Symptoms in Male Rats.Cell biochemistry and biophysics · 2024Article
- Isolation and Evaluation of Erinacine A Contents in Mycelia ofFoods (Basel, Switzerland) · 2024Article
- Review
- Mushroom-derived bioactive components with definite structures in alleviating the pathogenesis of Alzheimer's disease.Frontiers in pharmacology · 2024Review
- Biologically active secondary metabolites from white-rot fungi.Frontiers in chemistry · 2024Review
- Neurotrophic and Neuroprotective Effects ofInternational journal of molecular sciences · 2023Review
- Comprehensive Review of Nutraceuticals against Cognitive Decline Associated with Alzheimer's Disease.ACS omega · 2023Review
- Tracing the Path between Mushrooms and Alzheimer's Disease-A Literature Review.Molecules (Basel, Switzerland) · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hericium erinaceus was used in traditional Chinese medicine for physiologically beneficial medicines. Recently, it has become a candidate in causing positive brain health-related activities. We previously reported that Hericium erinaceus mycelium ameliorates Alzheimer's disease (AD)-related pathologies. To reveal the role of the cyanthin diterpenoid and sesterterpene constituents on this effects, erinacine A and S were isolated and their effects on attenuating AD-related pathology in APPswe/PS1dE9 transgenic mice were investigated. A 30 day short-term administration of erinacine A and S were performed to explore the effect of each erinacine on AD-related pathology including amyloid β production and degradation, plaque formation, plaque growth, glial activation and neurogenesis deterioration. Our results indicated the benefit effects of both erinacine A and S in cerebrum of APPswe/PS1dE9 mice, including: (1) attenuating cerebral plaque loading by inhibiting plaque growth; (2) diminishing the activation of glial cells; (3) raising the level of insulin degrading enzyme; and (4) promoting hippocampal neurogenesis. Moreover, erinacine A reduced the level of insoluble amyloid β and C-terminal fragment of amyloid precursor protein which was not mediated by erinacine S. We further performed a long term administration of erinacine A and found that erinacine A recovered the impairment in the tasks including burrowing, nesting, and Morris water maze. Our data pointed out that although both erinacine A and S reduce AD pathology via reducing amyloid deposition and promoting neurogenesis, erinacine A can also inhibit amyloid β production and is worth to be further developed for AD therapeutic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.